Review Article
Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
Table 1
Characteristics of studies included meta-analysis.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E: esomeprazole, O: omeprazole, PPI: proton pump inhibitor, P: pantoprazole, RBC: ranitidine bismuth citrate, B: bismuth, A: amoxicillin, L: levofloxacin, R: rifabutin, T: tetracycline, M: metronidazole, F: furazolidone, and C: clarithromycin. C: culture; UBT: urea breath test; H: histology. ФITT: intention to treat; ◊PP: per protocol. The six letters in the risk of bias assessment columns stand for bias of sequence generation, allocation concealment, blinding of participants, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting, respectively. Y: a low risk of bias; N: a high risk of bias; U: an uncertain risk of bias. Rescue: rescue therapy, second: second-line therapy, third: three-line therapy, fourth: fourth-line therapy. “—”: not reported. |